



Company Research 22 October 2023 18:09 HK

CreditAccess Grameen Ltd (CRDE.NS)

India | Banks

Ticks all boxes | Guidance upgraded

CREDAG continues to post strong numbers – a beat of ~10% to our PAT estimate; RoA/RoE of 5.6%/25%; AUM growth of 3% QoQ, 36% YoY; NIM expansion (10bps QoQ) and asset quality improvement (GNPA declined 10bps QoQ). Its business has further strengthened with continued geographic expansion (entered AP and TL) and liabilities diversification. It will be scaling new initiatives around secured MSME, 2W, gold and affordable housing which will further de-risk the business and provide scalability. H1 results show its cross-cycle RoA/RoE have improved structurally on better margin, leading to it upgrading its FY24E RoE guidance to 24%-25%. We upgrade PAT estimates by 3-5% and TP to Rs1600. BUY.

- Strong AUM & client growth: AUM grew 36% YoY, aided by growing client base (up 21% YoY). QoQ AUM growth (+3%) was moderate due to seasonality. Client base grew 4% QoQ. Client acquisition remains strong 0.34mn for Q2.
- Geographic diversification continuing: The share of KN, MH and TN have decreased from 77.2% in Q2FY23 to 73.5% in Q2FY24. ~40% of new customer addition is outside of top 3 states. It entered TL and AP in contiguous districts.
- NIM improvement behind: NIMs expanded 10bps QoQ to 13.1%. Management guided for CoF peaking out at current level of 9.8%. However, it expects NIM to contract to 12.7-12.8% in the coming quarters due to higher leverage. We believe NIMs to remain at ~13% vs ~12% in spread cap era.
- AQ remained best in class with GNPA declining 10bps QoQ to 0.8% and NNPA being at 0.2%. PAR0 increased 10bps QoQ to 1.3% however PAR30/60/90 declined 10bps QoQ. These numbers are the best in the industry in our view. It has strong controls in form of strong audit and risk teams.
- Liabilities diversification continues: It has been diversifying liabilities by increasing share of a) foreign sources of funding and b) retail NCDs. This, we believe, is one of the key differentiations with other MFIs and key to scalability.
- Upgrade estimates & TP: We upgrade PAT ests by 3%-5% and TP to Rs 1600. It trades at 2.7x FY25E P/B. We see incremental returns to be linked to BVPS compounding which we expect at ~27% CAGR (FY23-FY26E). BUY

BUY

Price: INR1389.55

Target: INR1600.00 (prev: INR1550.00) Forecast Total Return: 15.1%

Market Cap: INR221bn

Average daily volume: 283k

Nidhesh Jain +91 (22) 6849 7422

nidhesh.jain@investec.co.in Investec Capital Services (India) Pvt. Ltd

Bhuvnesh Gard

+91 (22) 6849 7559 bhuvnesh.garg@investec.co.in Investec Capital Services (India) Pvt. Ltd


Udav Pai

+91 (22) 6849 7499 uday.pai@investec.co.in Investec Capital Services (India) Pvt. Ltd

Financials and valuation				Year end:	31 March
	2022A	2023A	2024E	2025E	2026E
Net interest income	15,832	22,365	32,486	40,734	51,000
Total income	17,660	23,379	33,985	42,485	53,043
Pre provision profit	10,775	15,064	22,972	28,524	36,039
PBT (normalised) (INRm)	4,808	11,054	19,065	23,866	29,784
Profit after tax (INRm)	3,531	8,261	14,298	17,899	22,338
EPS (norm. cont.) - FD (INR)	22.3	52.0	90.0	112.6	140.6
BVPS (INR)	267.3	321.4	411.4	524.0	664.6
DPS (INR)	0.0	0.0	0.0	0.0	0.0
P/BVPS	5.2	4.3	3.4	2.7	2.1
ROA (%)	2.2	4.3	6.0	6.0	6.0
ROE (%)	9.7	19.4	26.3	25.4	24.6
Dividend yield (%)	0.0	0.0	0.0	0.0	0.0

Source: Company accounts, Investec Equities estimates

Price Performance



	1m	3m	12m
Price	5.4	5.9	44.9

Source: FactSet



Figure 1: Highlights for the quarter

Particulars	Comments
Profit	CREDAG reported PAT of Rs 3.5bn (up 97% YoY, up 0% QoQ), a beat of 11% on our estimates
	PPOP increased 68% YoY (up 4% QoQ), a beat of 11% on our estimates
Growth	Disbursements grew 14% YoY (up 4% QoQ) to Rs 49.7bn
Glowth	AUM was up 36% YoY, up 3% QoQ to Rs 224.9bn
	NII increased 50% YoY (up 1% QoQ), a beat of 2% on our estimates
Margins	Yield was up 40bps QoQ to 21.1%, CoF increased by 20bps QoQ to 9.8%
	Spread improved by 20bps QoQ to 11.3%
Operating expenses	Opex rose 26%YoY up 7 %QoQ
Operating expenses	Opex/Avg AUM declined 43bps YoY, (up 16bps QoQ) to 4.7%
	GNPA declined 12bps QoQ to 0.8%, NNPA declined 3bps QoQ to 0.2%
Asset quality	Credit Cost increased 30 bps QoQ to 1.7%
	PAR0 increased 10bos QoQ to 1.3% and PAR 30declined 10bps QoQ to 0.9%
	RoA and RoE stood at 5.6% and 24.7%
Return Ratios & Capital Adequacy	CRAR stood at 25%
Valuations	CREDAG trades at 2.8x FY25E P/B and 12x FY25E P/E

Source: Investec Securities estimates



Figure 2: Quarterly results summary

Oustanding/client (Rs)

P&L (Consol, Rs mn)	Q2FY23	Q3FY23	Q4FY23	Q1FY24	Q2FY24	YoY	QoQ
Interest Income	7,890	8,816	10,364	11,490	11,961	52%	4%
Interest Expense	2,732	3,142	3,456	3,849	4,239	55%	10%
Net Interest Income	5,158	5,674	6,908	7,641	7,722	50%	1%
Total Income	5,411	5,955	7,206	7,858	8,237	52%	5%
Employee Cost	1,297	1,271	1,345	1,563	1,618	25%	3%
Other Operating expenses	642	763	707	758	871	36%	15%
Depreciation	128	126	125	121	123	-4%	2%
Total Expenses	2,067	2,160	2,177	2,442	2,611	26%	7%
Operating Profit	3,344	3,795	5,029	5,416	5,626	68%	4%
Provisions	1,054	894	1,053	764	959	-9%	25%
PBT	2,290	2,900	3,975	4,652	4,668	104%	0%
Tax	529	743	1,010	1,189	1,197	126%	1%
PAT	1,761	2,158	2,966	3,463	3,470	97%	0%
Key Assets (Consol, Rs mn)	Q2FY23	Q3FY23	Q4FY23	Q1FY24	Q2FY24	YoY	QoQ
Gross Loan Portfolio	165,390	177,860	210,310	218,140	224,880	36%	3%
Disbursement	43,750	48,470	71,710	47,710	49,660	14%	4%
Key Ratios (Consol)	Q2FY23	Q3FY23	Q4FY23	Q1FY24	Q2FY24	YoY	QoQ
Yield on Loans (%)	19.0%	19.6%	19.7%	20.7%	21.1%	210	40
Cost of Funds (%)	9.2%	9.6%	9.5%	9.6%	9.8%	60	20
Spread	9.8%	10.0%	10.2%	11.1%	11.3%	150	20
NIM (%)	12.0%	11.9%	12.2%	13.0%	13.1%	110	10
Opex/AUM	5.1%	5.0%	4.5%	4.6%	4.7%	(43)	16
Credit Cost	2.6%	2.1%	2.2%	1.4%	1.7%	(89)	30
RoA	4.0%	4.5%	5.5%	5.8%	5.6%	160	(20)
RoE	16.1%	18.4%	24.0%	26.4%	24.7%	860	(170)
Gross NPL (%)	2.2%	1.7%	1.2%	0.9%	0.8%	(140)	(12)
Provisioning	2.5%	2.0%	1.8%	0.6%	0.5%	(193)	(9)
Net NPL (%)	0.8%	0.6%	0.4%	0.3%	0.2%	(52)	(3)
CAR (%)	25.0%	24.9%	23.6%	24.4%	25.0%	-	60
Tier-1 (%)	24.3%	24.0%	22.7%	23.5%	24.1%	(20)	60
Key Datapoints (Consol)	Q2FY23	Q3FY23	Q4FY23	Q1FY24	Q2FY24	YoY	QoQ
Employees	16,018	16,807	16,759	17,391	19,241	20%	11%
Branches	1,684	1,727	1,786	1,826	1,877	11%	3%
No. of active clients (mn)	3.8	3.9	4.3	4.4	4.6	21%	4%

43,547

45,154

49,322

49,319

48,855

Source: Company, Investec Securities estimates Note: Data represent calculated ratios


12%

-1%




Key Charts

Figure 3: Healthy disbursement on YoY basis




Source: Company, Investec Securities estimates

Figure 5: NIM improved in Q2FY24.




Source: Company, Investec Securities estimates

Figure 7: GNPA and NNPA improved further in Q2FY24.




Source: Company, Investec Securities estimates

Figure 4: AUM growth remains strong




Source: Company, Investec Securities estimates

Figure 6: Opex/AUM increased due to seasonality



Source: Company, Investec Securities estimates

Figure 8: RoE improved structurally



Source: Company, Investec Securities estimates



Figure 9: Du Pont - Expect RoE to remain in 24-25% in the medium term

Du Pont - AUM	FY19	FY20	FY21	FY22	FY23	FY24E	FY25E	FY26E
Interest Income	20.8%	17.1%	18.8%	17.0%	18.3%	21.0%	21.1%	21.1%
Interest Costs	6.9%	6.1%	7.3%	6.5%	6.4%	7.3%	7.4%	7.4%
Net Interest Income	14.0%	11.0%	11.5%	10.5%	11.9%	13.7%	13.7%	13.7%
Fee Income and Others	0.3%	0.8%	0.5%	1.2%	0.5%	0.6%	0.6%	0.5%
Total Income	14.3%	11.8%	12.0%	11.7%	12.4%	14.3%	14.2%	14.3%
Employee Costs	3.1%	2.7%	3.0%	2.9%	2.7%	2.8%	2.9%	2.8%
Other Opex	1.8%	1.7%	1.6%	1.7%	1.7%	1.8%	1.8%	1.7%
Total Opex	4.8%	4.5%	4.6%	4.6%	4.4%	4.6%	4.7%	4.6%
PPOP	9.4%	7.3%	7.4%	7.1%	8.0%	9.7%	9.6%	9.7%
Credit costs	1.2%	2.5%	6.0%	4.0%	2.1%	1.6%	1.6%	1.7%
PBT	8.2%	4.8%	1.4%	3.2%	5.9%	8.0%	8.0%	8.0%
Tax Rate	35%	27%	27%	27%	25%	25%	25%	25%
PAT	5.3%	3.5%	1.0%	2.3%	4.4%	6.0%	6.0%	6.0%
Leverage	3.2	4.0	4.3	4.1	4.4	4.4	4.2	4.1
RoE	16.9%	14.0%	4.4%	9.7%	19.4%	26.3%	25.4%	24.6%

Source: Investec Securities estimates

Figure 10: Change in our PAT estimates

		Old			New			% Change	
Rs mn	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E
Loan Book (AUM)	269,122	337,738	417,018	264,889	331,685	412,171	-2%	-2%	-1%
Net Interest Income	32,289	40,809	50,957	32,486	40,734	51,000	1%	0%	0%
Total Income	32,787	41,369	51,585	33,985	42,485	53,043	4%	3%	3%
Operating expenses	10,868	13,715	16,461	11,013	13,961	17,004	1%	2%	3%
Operating Profit	21,919	27,654	35,124	22,972	28,524	36,039	5%	3%	3%
Provisions & write- offs	3,777	4,754	6,297	3,907	4,659	6,254	3%	-2%	-1%
PAT	13,607	17,175	21,620	14,298	17,899	22,338	5%	4%	3%
EPS	86	108	136	90	113	141	5%	4%	3%
BVPS	383	491	627	388	500	641	1%	2%	2%

Source: Investec Securities estimates



Return on equity

Summary Financial		0000	00045	Year end:	
P&L Summary	2022	2023	2024E	2025E	2026E
Net interest income Non interest income	15,832 1,828	22,365 1,014	32,486 1,498	40,734 1,751	51,000 2,043
Total income	1,020	23,379	33,985	42,485	53,043
Wage costs	4,377	5,152	6,720	8,678	10,547
Other costs	2,508	3,162	4,293	5,283	6,457
Operating expenses	6,885	8,315	11,013	13,961	17,004
Pre provision profit	10,775	15,064	22,972	28,524	36,039
Provisions	5,967	4,010	3,907	4,659	6,254
Profit before tax	4,808	11,054	19,065	23,866	29,784
Income tax expense	1,277	2,794	4,766	5,966	7,446
Profit after tax (INRm)	3,531	8,261	14,298	17,899	22,338
Normalised net income	450	450	450	450	450
Total number of shares in issue (m)	156	159	159	159	159
EPS (reported) DPS (INR)	22.3 0.0	52.0 0.0	90.0 0.0	112.6 0.0	140.6 0.0
* *					
Balance Sheet Summary	2022	2023	2024E	2025E	2026E
Equity	1,559	1,589	1,589 63.770	1,589	1,589
Reserves & Surplus Networth	40,110 41.669	49,481 51,070	63,779 65,368	81,678 83,267	104,016 105,606
Minority interest	41,009	0	05,500	03,207	005,000
Borrowing	129,205	163,123	200,691	249.755	308,267
Total Liabilities	170,874	214,192	266,059	333,022	413,872
Fixed assets	2,563	2,273	2,500	2,750	3,025
Investments	5	4,545	5,909	6,500	7,150
Advances	147,653	190,433	237,642	299,729	374,777
Other assets	5,311	4,566	4,566	4,566	4,566
Net current assets	15,342	12,375	15,442	19,477	24,354
Total Assets	170,874	214,192	266,059	333,022	413,872
Asset under management	165,990	210,310	264,889	331,685	412,171
Disbursements	154,660	185,390	235,445	291,952	359,101
Key ratios	2022	2023	2024E	2025E	2026E
Yields	19.4	19.7	22.6	22.7	22.6
Cost of funds	8.2	8.3	9.6	9.8	9.8
Spread	11.1	11.4	13.0	12.9	12.8
NIM	10.5	11.9	13.7	13.7	13.7
Asset quality	2.0	4.0	0.0	4.0	0.0
Gross NPAs (%)	3.6	1.2	0.6	1.0	0.0
Net NPAs	1.3	0.4	0.4	0.4	0.4
Provision coverage ratio	64.4	65.7	36.0	62.8	
Efficiency ratios	20.0	25.6	20.4	20.0	20.4
Cost to Income	39.0	35.6 62.0	32.4 61.0	32.9 62.2	32.1 62.0
Wage costs/Total operating costs	63.6 1.3	1.4	1.6	1.6	1.5
Operating cost / Avg advances Capital ratios	1.3	1.4	1.0	1.0	1.3
Tier-1 capital	21.8	21.1	22.0	22.6	23.1
Tier-2 capital	1.0	1.0	1.0	1.0	1.0
Capital adequacy ratio	22.8	22.1	23.0	23.6	24.1
Dupont (as % of Avg assets)	22.0	22.1	23.0	23.0	24.1
NII	9.9	11.6	13.5	13.6	13.7
Other income	0.7	0.2	0.5	0.4	0.4
Total income	10.6	11.8	14.0	14.0	14.1
Employee exp	2.7	2.7	2.8	2.9	2.8
Non-employee exp	1.6	1.6	1.8	1.8	1.7
Operating profit	6.3	7.5	9.4	9.4	9.5
Provisions	3.7	7.5 2.1	1.6	1.6	9.5 1.7
PBT	2.5	5.4	7.8	7.8	7.8
וטו	2.0	0.4			
	ΛZ	11	1 2	1 X	
(1-tax rate)	0.3	1.1	1.8 6.0	1.8 6.0	1.9
(1-tax rate) Return on assets Leverage (x)	0.3 2.2 4.4	1.1 4.3 4.5	1.8 6.0 4.4	1.8 6.0 4.2	6.0 4.1

9.7

19.4

Source: Company accounts, Investec Equities estimates

25.4

24.6

26.3



Calendarised Valuation

Caleridarised valuation				Year end:	31 March
Valuation metrics	2022	2023	2024E	2025E	2026E
PE (x)	62.3	26.7	15.4	12.3	9.9
P/BV (x)	5.2	4.3	3.4	2.7	2.1
ROE (%)	9.7	19.4	26.3	25.4	24.6
ROA (%)	2.2	4.3	6.0	6.0	6.0
Dividend yield (%)	0.0	0.0	0.0	0.0	0.0
BVPS (INR)	267.3	321.4	411.4	524.0	664.6
EPS (norm. cont.) – FD (INR)	22.3	52.0	90.0	112.6	140.6
DPS (INR)	0.0	0.0	0.0	0.0	0.0
Dividend pay-out ratio	0	0	0	0	0

Source: Company accounts, Investec Equities estimates

Ratios and Metrics

Year end: 31 March

Source: Company accounts, Investec Equities estimates

Target Price Basis

Excess return on equity

Key Risks

Competition; Event Risk



Third party research disclosures

This report has been produced by a non-member affiliate of Investec Securities (US) LLC and is being distributed as third-party research by Investec Securities (US) LLC in the United States. In the United States, this report is not intended for use by or distribution to entities that do not meet the definition of a Major US Institutional Investor, as defined under SEC Rule 15a-6, or an Institutional Investor, as defined under FINRA rule 4512 (c), or for use by or distribution to any individuals who are citizens or residents of the United States.

Investec Securities (US) LLC accepts responsibility for the issuance of this report when distributed in the United States to entities who meet the definition of a US Major Institutional Investor or an Institutional Investor.

Investec Europe Limited distribute this report to European Economic Area clients as third party research under relevant regulations.

Analyst certification

Each research analyst responsible for the content of this research report, in whole or in part, and who is named herein, attests that the views expressed in this research report accurately reflect his or her personal views about the subject securities or issuers. Furthermore, no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in this research

SEC Regulation Best Interest

If you are a United States "retail investor," as defined by the Securities and Exchange Commission ("SEC") Regulation Best Interest, please click here to download SEC Form CRS for important information before you invest.

Managing conflicts

Investec has investment banking relationships with a number of companies covered by our Research department. In addition we may seek an investment banking relationship with companies referred to in this research. As a result investors should be aware that the firm may have a conflict of interest which could be considered to have the potential to affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

Disclosures

Research recommendations framework

Investec Equities bases its investment ratings on a stock's expected total return (ETR) over the next 12 months (with total return defined as the expected percentage change in price plus the projected dividend yield). Our rating bands take account of differences in costs of capital, risk premia and required rates of return in the various markets that we cover. Our rating systems for issuers are based on the frameworks set out in the tables below.

Stock ratings for European/Hong Kong stocks		Stock ratings for	r research produ	uced by Invest	tec Bank plc
	Expected total return	1	All stocks	Corp	orate stocks
	12m performance	Count	% of total	Count	% of total
Buy	greater than 10%	298	79%	111	37%
Hold	0% to 10%	59	16%	0	0%
Sell	less than 0%	18	5%	0	0%

Source: Investec Equities estimates

Stock ratings for Indian stocks	St	ock ratings for	research produ	ced by Invest	ec Bank plc	
	Expected total return		All stocks	Corp	Corporate stocks	
	12m performance	Count	% of total	Count	% of total	
Buy	greater than 15%	129	54%	1	1%	
Hold	5% to 15%	75	31%	0	0%	
Sell	less than 5%	36	15%	0	0%	

Source: Investec Equities estimates

Stock ratings for African* stocks	Stock ratings for research produced by Investec Markets (Pty) Lim						
	Expected total return All stocks			Corporate stocks			
	12m performance	Count	% of total	Count	% of total		
Buy	greater than 15%	41	52%	13	32%		
Hold	5% to 15%	18	23%	4	22%		
Sell	less than 5%	20	25%	7	35%		

*For African countries excluding South Africa, ratings are based on the 12m implied US dollar expected total return (ETR). This is derived from the expected local currency (LCY) ETR by making assumptions on the 12month forward exchange rates for the respective currencies. For South African stocks, ratings are based on the ETR in rand terms.

For European and Hong Kong stocks, within the Hold banding, an Add rating may be (optionally) applied if the analyst is positive on the stock and the ETR is greater than 5%; a Reduce rating may be (optionally) applied if the analyst is negative on the stock and the ETR is less than 5%.

Not rated (N/R) is applied to any stock where we have no formal rating and price target. Under Review (U/R) can be applied to an analyst's rating, price target and/or forecasts for a limited time period and indicates that new information is available that has not yet been fully digested by the analyst. We regularly review ratings across our coverage universe as we seek to ensure price targets and ratings remain aligned. However, during periods of market, sector or stock volatility, we may allow minor deviations from our recommendation framework to persist on a temporary basis to avoid a high frequency of rating changes arising from rapid share price movements.

The subject company may have been given access to a pre-published version of this report (with recommendation and price target redacted) to verify factual information only.

Investec Equities research contains target prices and recommendations which are prepared on a 12 month time horizon, and therefore may not reflect the different circumstances, objectives and investment time horizons of those who receive it. Investors should therefore independently evaluate whether the investment(s) discussed is (are) appropriate for their specific needs. In addition, the analysts named in this report may from time to time discuss with our clients, including Investec salespersons and traders, or may discuss in this report, trading strategies that reference near term catalysts or events which they believe may have an impact in the shorter term on the market price of securities discussed in this report. These trading strategies may be directionally counter to the analyst's published target price and recommendation for such issuers.

For price target bases, risks to the achievement of our price targets and for full disclosures, including any company mentioned herein, please visit: http://researchpdf.investec.co.uk/Documents/WDisc.pdf

Investec may act as a liquidity provider or as a systematic internaliser in the securities of the subject company/companies included

Our policy on managing actual or potential conflicts of interest in the United Kingdom can be found at:

https://www.investec.co.uk/legal/uk/conflicts-of-interest.html
Our policy on managing actual or potential conflicts of interest in South Africa can be found at:

http://www.investec.co.za/legal/sa/conflicts-of-interest.html




Company disclosures

CreditAccess Grameen Ltd

Key: ● Investec has received compensation from the company for investment banking and/or brokerage services within the past 12 months, ◆ Investec expects to receive or intends to seek compensation from the company for investment banking services, <\ \text{Investec} has been involved in managing or co-managing a publicly disclosed offer of the company's securities in the past 12 months, ● Investec makes a market in the securities of the company, \(\ext{ell Investec} has 1\) of common equity securities in the company, \(\ext{ell Investec} holds more than 1\) of common equity securities in the company, the company holds more than 5\% of common equity securities in Investec, \(\ext{ell The analyst} (or connected persons) has a holding in the subject company, \(\ext{ell Investec} holds a net long position in excess of 0.5\% of the total issued share capital of the company, \(\ext{ell Investec} holds a holding in the company. \(\ext{ell Investec} holds more than 1\) of the debt instruments of the company. \(\ext{ell Investec} holds more than 1\) of the debt instruments of the company.



Recommendation history (for the last 3 years to previous day's close) CreditAccess Grameen Ltd (CRDE.NS) – Rating Plotter as at 22 Oct 2023



Source: Investec Equities, FactSet



Investec Equities:

In the United Kingdom refers to Investec Equities a division of Investec Bank plc.

Investec Bank plc is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority and is a member of the London Stock Exchange

Registered in England No. 489604

Registered Office Address:

30 Gresham Street London EC2V 7QP
In the EEA refers to Investec Europe Limited trading as Investec Europe and is regulated by the Central Bank of Ireland. Registration No. 222173.

Registered Office Address:

The Harcourt Building, Harcourt Street, Dublin 2, Ireland

In South Africa refers to:

Investec Bank Limited an authorised financial services provider and a member of the JSE.

Registered in South Africa No. 1969/004763/06

Investec Markets (Pty) Limited an authorised financial services provider and a member of the JSE.

Registered in South Africa No. 2018/243092/07

Registered Office Address: 100 Gravston Drive Sandown, Sandton 2196, South Africa

In India refers to Investec Capital Services (India) Private Limited, engaged in businesses of equities, corporate finance and private credit and which is registered with the Securities and Exchange Board of India, the Capital Market regulator in India as a (i) Research Analyst with registration number INH000000263; (ii) Category-I Merchant Banker with registration number INM000011971; and (iii) Stock Broker with registration number INZ000007138.

Registered Office Address: Investec Capital Services (India) Private Limited Parinee Crescenzo, C 38 & 39, "G" Block, 11th flr , B Wing , Unit No 1103 & 1104 Bandra Kurla Complex, Mumbai - 400 051, India

In Singapore refers to Investec Singapore Pte. Ltd. an exempt financial adviser which is regulated by the Monetary Authority of Singapore as a capital markets services licence holder. Registration No. 201634931E

Registered Office Address: 71. Robinson Road

Singapore 068895

In the United States refers to Investec Securities (US) LLC.

Registered Office Address: 10 East 53rd Street, 22nd Floor New York, NY 10022

Further details of Investec office locations, including postal addresses and telephone contact details: https://www.investec.com/en_gb/welcome-to-investec/contactus.html

Analyst(s)

Nidhesh Jain +91 (22) 6849 7422 nidhesh.jain@investec.co.in Bhuvnesh Garg +91 (22) 6849 7559 bhuvnesh.garg@investec.co.in

Important Disclaimer – please read

For the purposes of this disclaimer, "Investec Equities" shall mean: (i) Investec Bank plc ("IBP"); (ii) Investec Bank Limited ("IBL"); (iii) Investec Markets (Pty) Limited ("IML"); (iv) Investec Capital Services (India) Private Limited; (v) Investec Singapore Pte. Ltd ("ISPL"); (vi) Investec Europe Limited; and (vii) Investec Securities (US) LLC and from time to time, in relation to any of the forgoing entities, the ultimate holding company of that entity, a subsidiary (or a subsidiary of a subsidiary) of that entity, a holding company of that entity or any other subsidiary of that holding company, and any affiliated entity of any such entities. "Investec Affiliates" shall mean any directors, officers, representatives, employees, advisers or agents of any part of Investec Equities. This research report has been issued solely for general information and should not be considered as an offer or solicitation of an offer to sell, buy or subscribe to any securities or any derivative instrument or any other rights pertaining thereto.

This research may have been issued to you by one entity within Investec Equities in the fulfilment of another Investec Equities

entity's agreement to do so. In doing so, the entity providing the research is in no way acting as agent of the entity with whom you have any such agreement and in no way is standing as principal or a party to that arrangement. The information in this report has been compiled by Investec Equities from sources believed to be reliable, but neither Investec Equities nor any Investec Affiliates accept liability for any loss arising from the use hereof or makes any representations as to its accuracy and completeness. Any opinions, forecasts or estimates herein constitute a judgement as at the date of this report. There can be no assurance that future results or events will be consistent with any such opinions, forecasts or estimates. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied is made regarding future performance. The information in this research report and the report itself is subject to change without notice.

This research report as well as any other related documents or information may be incomplete, condensed and/or may not contain

all material information concerning the subject of the research and/or its group companies (including subsidiaries): its accuracy cannot be guaranteed. Investec Equities has no obligation to update, modify or amend this research report or to otherwise notify a recipient thereof if an opinion, forecast or estimate changes or becomes inaccurate. Coverage and the frequency of changes in market conditions and in both general and company-specific economic prospects make it difficult to update research at defined intervals. Updates are at the sole discretion of the analyst or the Head of Research and reports may be published at irregular intervals. Investec Equities (or its directors, officers or employees) may, to the extent permitted by law, own or have a position in the securities or financial instruments (including derivative instruments or any other rights pertaining thereto) of any company or related company referred to herein, and may add to or dispose of any such position or may make a market or act as a principal in any transaction in such securities or financial instruments. Directors of Investec Equities may also be directors of any of the companies mentioned in this report. Investec Equities may from time to time provide or solicit investment banking, underwriting or other financial services to, for or from any company referred to herein. Invested Equities (or its directors, officers or employees) may, to the extent permitted by law, act upon or use the information or opinions presented herein, or research or analysis on which they are based prior to the material being published. Investec Equities may have issued other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Those reports reflect the different assumptions, views and analytical methods of the analysts who prepared them. The value of any securities or financial instruments mentioned in this report can fall as well as rise. Foreign currency denominated securities and financial instruments are subject to fluctuations in exchange rates that may have a positive or adverse effect on the value, price or income of such securities or financial instruments. Certain transactions, including those involving futures, options and other derivative instruments, can give rise to substantial risk and are not suitable for all investors. This report does not contain advice. Specifically, it does not take into account the objectives, financial situation or needs of any particular person. Investors should not do anything or forebear to do anything on the basis of this report. Before entering into any arrangement or transaction, investors must consider whether it is appropriate to do so based on their personal objectives, financial situation and needs and seek financial advice where needed.

No representation or warranty, express or implied, is or will be made in relation to, and no responsibility or liability is or will be accepted by Investec Equities or any Investec Affiliates as to, or in relation to, the accuracy, reliability, or completeness of the contents of this research report and each entity within Investec Equities (for itself and on behalf of all Investec Affiliates) hereby expressly disclaims any and all responsibility or liability for the accuracy, reliability and completeness of such information or this research report generally

The securities or financial instruments described herein may not have been registered under the US Securities Act of 1933, and may not be offered or sold in the United States of America or to US persons unless they have been registered under such Act, or except in compliance with an exemption from the registration requirements of such Act. US entities that are interested in trading securities listed in this report should contact a US registered broker dealer.

This report and the distribution of this report do not constitute an offer or an invitation to offer to the Hong Kong or Singaporean public to acquire, dispose of, subscribe for or underwrite any securities or related financial instruments. Neither this research report nor the information contained in it is intended to be an offer to any person, or to induce or attempt to induce any person to enter into or to offer to enter into any agreement for or with a view to acquiring, disposing of, subscribing for or underwriting securities. The distribution of this document in other jurisdictions may be prohibited by rules, regulations and/or laws of such jurisdiction. Any failure to comply with such restrictions may constitute a violation of United States securities laws or the laws of any such other jurisdiction. For readers of this report in: South Africa: this report is produced by IBL an authorised financial services provider and a member of the JSE Limited. Europe Economic Area: this report is distributed by Investec Europe Limited, an investment firm authorised by the Central Bank of Ireland, this report may only be distributed to professional clients and eligible counterparties as defined in MiFID Il and is not intended for retail clients. United Kingdom: this report is produced by IBP and was prepared by the analyst named in this report. IBP is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. This report may only be issued to professional clients, eligible counterparties and investment professionals, as described in S19 of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005 and is not intended for retail clients. Hong Kong: this report is distributed in Hong Kong by Templewater Hong Kong Limited, a Securities and Futures Commission licensed corporation (Central Entity Number AFT069) and is intended for distribution to professional investors (as defined in the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)) only. This report is personal to the recipient and any unauthorised use, redistribution, retransmission or reprinting of this report (whether by digital, mechanical or other means) is strictly prohibited. India: this report is issued by Investec Capital Services (India) Private Limited which is registered with the Securities and Exchange Board of India. Investec Capital Services (India) Private Limited had received an administrative warning letter from SEBI in 2020 pursuant to inspection carried out by SEBI for the year 2018-2019. **Singapore**: This report is produced by IBP and issued and distributed in Singapore through Investec Singapore Pte. Ltd., an exempt financial adviser which is regulated by the Monetary Authority of Singapore as a capital markets services licence holder. This material is intended only for, and may be issued and distributed in Singapore only to accredited investors and institutional investors, as defined in Section 4A of the Securities and Futures Act, Cap. 289 ("SFA"). This material is not intended to be issued or distributed to any retail or other investors. ISPL may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Singapore recipients of this document should contact ISPL at the above address in respect of any matters arising from, or in connection with, this report. Canada: this report is issued by IBP, and may only be issued to persons in Canada who are able to be categorised as a "permitted client" under National Instrument 31-103 Registration Requirements and Exemptions or to any other person to whom this report may be lawfully directed. This report may not be relied upon by any person other than the intended recipient

This publication is confidential for the information of the addressee only and may not be reproduced in whole or in part, copies circulated, or disclosed to another party, without the prior written consent of an entity within Investec Equities. Securities referred to in this research report may not be eligible for sale in those jurisdictions where an entity within Investec Equities is not authorised or permitted by local law to do so. In the event that you contact any representative of Investec Equities in connection with receipt of this research, including any analyst, you should be advised that this disclaimer applies to any conversation or correspondence that occurs as a result, which is also engaged in by Investec Equities and any relevant Investec Affiliate solely for the purposes of providing general information only. Any subsequent business you choose to transact shall be subject to the relevant terms thereof. We may monitor e-mail traffic data and the content of email. Calls may be monitored and recorded. Investec Equities does not allow the redistribution of this report to non-professional investors or persons outside the jurisdictions referred to above and Investec Equities cannot be held responsible in any way for third parties who effect such redistribution or recipients thereof. © 2023